Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer

In Sil Choi, Byung Su Kim, Sook Ryun Park, Sang Yoon Lee, Do Yeun Kim, Jee Hyun Kim, Se Hoon Lee, Tae You Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Purpose: We conducted this study to evaluate the activity and toxicity of a combination regimen of paclitaxel plus carboplatin in patients with advanced NSCLC aged 65 years or older and/or in those with an ECOG performance status (PS) 2. Materials and methods: Chemotherapy-naive patients with unresectable pathologically-proven NSCLC and of either age ≥65 or ECOG PS 2 were eligible. Patients received modified regimen with attenuated doses of paclitaxel (135 mg/m2 i.v. for 3 h D1) and carboplatin (AUC=5, D1) every 3 weeks. Results: Thirty-five patients were enrolled. Nineteen patients were aged 65 or older (54%) and 26 patients (74%) were ECOG PS 2. The objective response rate was 40% with 14 partial responses. The median time to progression was 22 weeks. Grade 3 leucopenia occurred in 1 cycle and one case of neutropenic fever. Conclusions: The modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy was effective and well tolerated in patients with advanced NSCLC aged 65 years or older and/or in those with ECOG PS 2.

Original languageEnglish
Pages (from-to)99-101
Number of pages3
JournalLung Cancer
Volume39
Issue number1
DOIs
StatePublished - 1 Jan 2003

Keywords

  • Carboplatin
  • Chemotherapy
  • Non-small cell lung cancer
  • Paclitaxel

Fingerprint

Dive into the research topics of 'Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this